Request Status



Your Authorization Request Has Been Approved

Your authorization request number is SC003246505. If you need to add a new chemotherapy drug, supportive care drug, or a new chemotherapy regimen, you will need to submit a new authorization request.

Authorization Status

Approved

Authorization Start Date

04-07-2022

Authorization Number

SC003246505

Authorization End Date

10-07-2022

	Drug Name	Drug Code	Authorization Status
		00069029301	Approved
Member Information			
Full Name	JOHN SMITH	Subscriber ID	1016498401
Gender	Male	Group ID	PAI2000
Date of Birth	01-09-1941	Relationship	Subscriber/Recipient

Requesting Provider Point of Contact **Provider Details Provider First Name THOMAS Full Name** Test **Provider Last Name** SMITH **Phone Number** 555-555-5555 **Provider TIN** 247757770 **Fax Number** 555-555-5555 **Provider NPI Email** 1174919963 PO BOX 635061, CINCINNATI OH Communication Type **Provider Address** 45263 **Request Received by** Phone

Provider Phone Number 555-555-5555

Provider Fax Number 555-555-5555

Provider Email

Provider Cell Phone

Servicing Provider

Same as requesting provider

Request Details

Backdating Start Date?

Authorization Start Date

ICD-10 Code

Performance Scale

No

04-07-2022

C49.A1 - Gastrointestinal stromal tumor of esophagus

Patient Details		Clinical Details	
Height of the Patient	55 in	Primary Cancer	Gastrointestinal Stromal Tumors (GISTs)
Weight of the Patient	55 lbs	Supportive Care Only Request	Yes
Patient Contact Number	555-555-5555 Ext. 6	What is the Drug Category?	White Blood Cell Growth Factors
Service Details		What is the Drug Name?	NIVESTYM SOLN 300.0 MCG/ML
Initial Diagnosis Date	04-2022		
Place of Service	Office		

Clinical Status

Please select indication for the White Blood Cell Colony Stimulating Factor (CSF)?

Bone marrow/stem cell transplant

*Reminder: Responses to questions must accurately reflect the member's medical record, and are subject to monitoring at any time. If an audit determines that false answers were provided during the authorization process, your facility may be responsible for repayment of any associated claims. Please attest that you are able to provide medical records that support the information provided in this authorization request.

Continue

Please choose indication from list below:

Mobilization of hematopoietic progenitor cells in combination with plerixafor in the autologous setting for patients with non-Hodgkin lymphoma or multiple myeloma

Supportive Drug

Drug Code	Drug Name	Drug Route	Dosage	Day(s) of Cycle to be Administered	Length of Cycles (Days or weeks)	Benefit Type	Cost Savings Programs
00069029301	Nivestym Soln 300.0 Mcg/ml	Subcutaneous	300 MCG/ML	1	1 day	Medical	

Treatment End Date 10-07-2022

Clinical Documentation

Is it an Urgent Request? No

The authorization provided is not a guarantee of payment to the provider. Payment is based on the patient's benefit plan and eligibility when the services are received.

Back to Dashboard